Medical insurance reimbursement conditions for Lenvatinib

The original drug Lenvatinib has been launched in China and has now entered the scope of Class B medical insurance through the relevant regulations of the National Medical Insurance Administration. The medical insurance reimbursement condition is for patients who meet the indications. Lenvatinib is a receptor tyrosine kinase inhibitor indicated for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma, endometrial cancer, and unresectable hepatocellular carcinoma in combination with everolimus. Lenvatinib is sold in China under the brand name of Lenvima. The price of each box of 4mg*30 tablets may be more than 3,000 yuan. The reimbursement ratio is different in different regions, and the price after reimbursement may be different.